wire - news in brief

« BACK

Life Sciences



Results 1 - 50 of 510.
1 2 3 4 5 ... 11 Next »

Medicine/Pharmacology - Life Sciences
18.01.2017
Unveiling the biology behind nonalcoholic fatty liver disease
Unveiling the biology behind nonalcoholic fatty liver disease
EPFL scientists have discovered a new biological mechanism behind nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease covers a range of diseases that result from fat accumulation in the liver, but not as a result of alcohol abuse. Fat buildup can lead to liver inflammation, scarring and irreversible damage, such as cirrhosis and liver failure.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Environment/Sustainable Development - Life Sciences
20.12.2016
University of Zurich to become global center for biodiversity research
University of Zurich to become global center for biodiversity research
Prof. Michael Schaepman, PhD Department of Geography University of Zurich Phone +41 44 635 51 60 E-mail Prof. Bernhard Schmid, PhD Institute of Evolutionary Biology and Environmental Studies
Life Sciences - Administration/Government
20.12.2016
Medicine/Pharmacology - Life Sciences
19.12.2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases Novartis to broaden liver portfolio to deliver best-in
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis drug Votubia recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)   Seizures are the most common TSC-relat
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications   Ilaris (canakinumab) is recommended for
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
Medicine/Pharmacology - Life Sciences
07.12.2016
Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now approved for nine distinct uses across six different types of cancer - Roche today announced that the U.S.
Medicine/Pharmacology - Life Sciences
07.12.2016
Novartis’ Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for vi
Medicine/Pharmacology - Life Sciences
06.12.2016
Novartis announces Zykadia first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC   Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%   Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients - Novartis today announced result
Medicine/Pharmacology - Life Sciences
05.12.2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 adults show potential of GP2013 as an alternative rituximab Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial.
Medicine/Pharmacology - Life Sciences
05.12.2016
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Syphilis has plagued humankind for over 500 years. After the first reported outbreaks struck Europe in 1495, the disease spread rapidly to other continents and swelled to a global pandemic. When treatment with the antibiotic penicillin became available in the mid-twentieth century, infection rates started to decrease dramatically.
Life Sciences - Medicine/Pharmacology
05.12.2016
Researchers uncover protein-based ‘cancer signature'
Researchers uncover protein-based ‘cancer signature’
A research team at the University of Basel's Biozentrum has investigated the expression of ribosomal proteins in a wide range of human tissues including tumors and discovered a cancer type specific signature. As the researchers report in ‘Genome Biology' this ‘cancer signature' could potentially be used to predict the progression of the disease.
Medicine/Pharmacology - Life Sciences
04.12.2016
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T'cell tr
Life Sciences - Media
02.12.2016
Evaluation of scientific rigor in animal research
Media releases, information for representatives of the media Media Relations (E) In the course of the ‘reproducibility crisis' in biomedical research, scientific rigor in animal reserach, and thus the ethical justification of animal experiments, has also been questioned. Commissioned by the Swiss Federal Food Safety and Veterinary Office (FSVO), researchers from the University of Bern have assessed scientific rigor in animal experimentation in Switzerland.
Medicine/Pharmacology - Life Sciences
28.11.2016
Successfully Treating Genetically Determined Autoimmune Enteritis
Using targeted immunotherapy, doctors have succeeded in curing a type of autoimmune enteritis caused by a recently discovered genetic mutation. This report comes from researchers at the Department of Biomedicine of the University of Basel and University Hospital Basel. Their results raise new possibilities for the management of diarrhea, which is often a side effect of melanoma treatment.
Life Sciences - Astronomy
26.11.2016
Discover your brain at planète santé
Discover your brain at planète santé
What does it feel like to recover from brain damage? Have you ever tricked your senses into sensing one thing but experiencing something entirely different? Walk inside a huge inflatable brain and play with optical illusions.
Medicine/Pharmacology - Life Sciences
18.11.2016
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks   Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy   Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA ** Holzkirchen, November 18, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced the publication of the EGALITY study in the British Journal of Dermatology .
Medicine/Pharmacology - Life Sciences
17.11.2016
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
The SNSF is launching the National Research Programme "Antimicrobial Resistance", which aims to develop new solutions to ensure that antibiotics remain effective. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. The aim of European Antibiotic Awareness Day on 18 November 2016 is to highlight the fact that medicines are losing their effectiveness as a result and that once easy-to-treat infections are turning into deadly diseases.
Life Sciences
17.11.2016
An added dimension to high school biology class
An added dimension to high school biology class
High school science classes are taking on an added dimension. EPFL startup Nanolive will run a competition to select three local high schools that will be given the use of the company's microscope, which is capable of observing living cells in real time and 3D.
Life Sciences
17.11.2016
Walking is bound hand and foot: How long projecting neurons couple the movement of our limbs
Walking is bound hand and foot: How long projecting neurons couple the movement of our limbs
We humans walk with our feet. This is true, but not entirely. Walking, as part of locomotion, is a coordinated whole-body movement that involves both the arms and legs. Researchers at the Biozentrum of the University of Basel and the Friedrich Miescher Institute for Biomedical Research have identified different subpopulations of neurons in the spinal cord with long projections.
Medicine/Pharmacology - Life Sciences
16.11.2016
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
First results from global registrational trial of CAR T'therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia  Sub-group analyses from pivotal MONALEESA-2 trial of LEE011 (ri
Life Sciences - Medicine/Pharmacology
15.11.2016
Drosophila innate immunity: another piece to the puzzle
Drosophila innate immunity: another piece to the puzzle
EPFL scientists have discovered a new receptor in the fruit fly immune system that detects bacterial infections. The finding opens up clues for our own immune responses. Our immune system has two phases: innate and adaptive. The first phase, innate, refers to the immediate defense mechanisms such as skin, blood chemicals and certain types of immune cells that constantly fight off foreign organisms to keep them from infecting us.
Medicine/Pharmacology - Life Sciences
15.11.2016
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence Research network of 21 academic centers from around the world to access and share technology, data and expertise
Agronomy/Food Science - Life Sciences
10.11.2016
Vacancies on Agroscope Executive Board all filled: Alain Gaume as Head of ‘Plant Pro-tection’
Bern, 10.11.2016 - Dr. Alain Gaume will be the new Head of Agroscope's ‘Plant Protection' Strategic Research Division.
Medicine/Pharmacology - Life Sciences
03.11.2016
Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting
Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro
Life Sciences - Medicine/Pharmacology
03.11.2016
How the liver dances to a day/night rhythm
How the liver dances to a day/night rhythm
Following the day-night cycle, the liver has its own metabolic rhythm. Using cutting-edge proteomics, scientists at EPFL and Nestlé Institute of Health Sciences have now identified over 500 liver proteins that change in abundance over the course of the day in the cell nucleus, opening a new dimension of metabolism.
Life Sciences - Medicine/Pharmacology
03.11.2016
Award for innovative cell culture technology
Award for innovative cell culture technology
Researchers at ETH Zurich have developed a new cell culture method, which may very well enable to forgo certain tests on animals in the future.
Life Sciences - Chemistry
02.11.2016
Chemists Create Clusters of Organelles by Mimicking Nature
Chemists Create Clusters of Organelles by Mimicking Nature
Scientists from the University of Basel have succeeded in organizing spherical compartments into clusters mimicking the way natural organelles would create complex structures.
Medicine/Pharmacology - Life Sciences
02.11.2016
Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting
Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting 15 oral presentations from 17 abstracts across six autoimmune cond
Medicine/Pharmacology - Life Sciences
01.11.2016
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared to
Life Sciences - Medicine/Pharmacology
28.10.2016
Bernese Biotechnology Has International Triumph
MRI data are essential in the treatment of neurological illnesses. Self-learning software from Bern respectively evaluates them so that the imaging of brain tumours, strokes and now also multiple sclerosis can profit from it.
Medicine/Pharmacology - Life Sciences
19.10.2016
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer First and only anti-PD-L1 cancer immunotherapy approved by the FDA for met
Life Sciences
19.10.2016
Overcoming egocentricity increases self-control
In the study, people chose between a payoff that only benefitted themselves and a payoff that benefitted them less but also benefitted another person. (Image: iStock.com/eljule). Should I buy a new car now or save the money for retirement? Such situations require self-control in order to resist the immediately tempting offer for the sake of more important outcomes in the future.
Medicine/Pharmacology - Life Sciences
09.10.2016
Novartis ALK+ metastatic NSCLC therapy Zykadia extends progression-free survival beyond 18 months in Phase II study
Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in ALKi
Medicine/Pharmacology - Life Sciences
08.10.2016
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups   Results showed that the combination significantly improved tumor
Medicine/Pharmacology - Life Sciences
05.10.2016
FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
FDA grants breakthrough therapy designation for Roche's Actemra/RoActemra in giant cell arteritis, a form of vasculitis Roche recently announced positive results from a Phase III GCA clinical trial Fourteenth Breakthrough Therapy designation for Roche medicines There have been no therapies approved for GCA in more than 50 years Roche , announced today that the U.S.
Life Sciences - Medicine/Pharmacology
04.10.2016
Developing brain regions in children hardest hit by sleep deprivation
Developing brain regions in children hardest hit by sleep deprivation
Sleep is vital for humans. If adults remain awake for longer than usual, the brain responds with an increased need for deep sleep. This is measured in the form of “slow wave activity” using electroencephalography (EEG). In adults, these deep-sleep waves are most pronounced in the prefrontal cortex – the brain region which plans and controls actions, solves problems and is involved in the working memory.
Life Sciences - Psychology
04.10.2016
Do Older People Take Fewer Risks?
Studies by the University of Basel have shown that whether and how risk-taking propensity varies over a person's life span depends in part on how risk taking is measured. When subjects are asked how they assess their risk propensity, a clear reduction with age is the result. However, this reduction is not necessarily observed for specific risk-taking tasks.
Medicine/Pharmacology - Life Sciences
04.10.2016
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC This second Alecensa Breakthrough Therapy Designation granted is based on phase 3 J-ALEX study Roche announced today that it has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib).
Medicine/Pharmacology - Life Sciences
03.10.2016
First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
First phase III data on Roche's TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress • Superiority results from the phase III OAK study comparing Tecentriq to chemotherapy in a difficult to treat type of lung cancer will be highlighted at the ESMO Presidential Symposium • Investigational cancer immunotherapy-based combination approaches across a range of cancer types to be showcased duri
1 2 3 4 5 ... 11 Next »